Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Chlorhexidine gluconate (4%)
Chlorhexidine gluconate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Chlorhexidine gluconate (4%) | DRUG | Chlorhexidine 4% solution will be applied from the neck down (avoiding the face, penis, and vagina), allowed to sit on the skin for one minute, then rinsed off in the shower every day for 5 days prior to surgery. |
| Mupirocin 2% Ointment | DRUG | Mupirocin 2% ointment will be applied to the inside of the nostrils twice daily, in the morning and evening, for 5 days prior to surgery. A small amount of the ointment will be placed on the tip of a cotton swab to facilitate application to each nostril. |
Chlorhexidine gluconate is being studied for the prevention of surgical wound infection, specifically in patients undergoing skin cancer surgery on the lower extremities. It is an investigational small molecule in Phase 3 clinical development for this indication.
Chlorhexidine gluconate is being developed by The Cooper Companies, Inc., a company traded on the New York Stock Exchange under the ticker COO. The company is conducting a Phase 3 clinical trial to evaluate the drug for surgical wound infection prevention.
Chlorhexidine gluconate is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trial is currently recruiting participants to study its effect on infection rates in lower extremity wounds.
Chlorhexidine gluconate is being evaluated in a Phase 3 clinical trial with the identifier NCT07142408. This trial is studying the effect of bacterial decolonization before skin cancer surgery on infection rates of lower extremity wounds left open to heal. The trial is currently recruiting and aims to enroll 848 participants.
Yes, Chlorhexidine gluconate is also known as Chlorhexidine gluconate (4%). The 4% formulation is the specific concentration being studied in the Phase 3 clinical trial for surgical wound infection prevention.